Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in active idiopathic inflammatory myopathies (VERANDA™-IIM)
NCT07789015Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2026
- Primary completion
- Mar 2030
- Countries
- 26
01
Overview
A Phase 3 trial of nerandomilast in idiopathic inflammatory myopathy (IIM), sponsored by Boehringer Ingelheim. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07789015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789015.